William Blair Weighs in on Neogen Co.’s FY2026 Earnings (NASDAQ:NEOG)

Neogen Co. (NASDAQ:NEOG) – Analysts at William Blair issued their FY2026 EPS estimates for shares of Neogen in a research report issued to clients and investors on Tuesday, April 9th. William Blair analyst B. Vazquez forecasts that the company will post earnings of $0.64 per share for the year. The consensus estimate for Neogen’s current full-year earnings is $0.50 per share.

Separately, Piper Sandler boosted their price objective on shares of Neogen from $17.50 to $19.00 and gave the stock a “neutral” rating in a research report on Thursday, January 18th.

Neogen Price Performance

Neogen stock opened at $12.38 on Friday. Neogen has a 52 week low of $12.18 and a 52 week high of $24.09. The company has a quick ratio of 2.63, a current ratio of 3.82 and a debt-to-equity ratio of 0.28. The firm’s 50-day simple moving average is $15.81 and its 200 day simple moving average is $16.72. The firm has a market capitalization of $2.68 billion, a PE ratio of 1,238.00 and a beta of 1.13.

Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Tuesday, April 9th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.02). Neogen had a return on equity of 3.35% and a net margin of 0.17%. The business had revenue of $228.80 million during the quarter, compared to analysts’ expectations of $230.01 million. During the same quarter in the prior year, the firm earned $0.12 earnings per share. Neogen’s quarterly revenue was up 4.8% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Neogen during the 1st quarter valued at about $451,277,000. Vanguard Group Inc. increased its stake in shares of Neogen by 9.3% during the 4th quarter. Vanguard Group Inc. now owns 19,546,737 shares of the company’s stock valued at $393,085,000 after acquiring an additional 1,663,125 shares during the last quarter. Norges Bank acquired a new position in shares of Neogen during the 4th quarter valued at about $365,794,000. Baillie Gifford & Co. acquired a new position in shares of Neogen during the 4th quarter valued at about $166,646,000. Finally, Select Equity Group L.P. acquired a new position in shares of Neogen during the 1st quarter valued at about $147,849,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Insider Buying and Selling at Neogen

In other news, Director James C. Borel bought 7,500 shares of Neogen stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of $13.06 per share, for a total transaction of $97,950.00. Following the acquisition, the director now owns 21,392 shares in the company, valued at $279,379.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director James C. Borel bought 7,500 shares of Neogen stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of $13.06 per share, for a total transaction of $97,950.00. Following the acquisition, the director now owns 21,392 shares in the company, valued at $279,379.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David H. Naemura bought 12,500 shares of Neogen stock in a transaction on Wednesday, April 10th. The stock was purchased at an average price of $12.51 per share, for a total transaction of $156,375.00. Following the completion of the acquisition, the chief financial officer now owns 30,040 shares in the company, valued at approximately $375,800.40. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 43,000 shares of company stock worth $538,605. Corporate insiders own 0.71% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.